Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel Switzerland 4070
- IPO Date
- Feb 13, 2009
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG develops, manufactures and markets pharmaceuticals and in vitro diagnostics worldwide. The company operates through its Pharmaceuticals and Diagnostics divisions; the Pharmaceuticals division offers prescription medicines addressing oncology, immunology, infectious diseases, ophthalmology, neuroscience, cardiovascular, renal and metabolic diseases, haemophilia, inflammatory and respiratory conditions; key products include monoclonal antibodies, antibody-drug conjugates and targeted therapies such as Tecentriq, Perjeta, Avastin, Hemlibra and Actemra; the Diagnostics division provides professional diagnostics systems and reagents for clinical chemistry, immunoassays, molecular diagnostics, tissue diagnostics and diabetes care including Accu-Chek glucose monitoring; additional offerings encompass point-of-care tests such as the recently FDA-cleared Bordetella infection diagnostic and sequencing technologies like those achieving Guinness World Record advances in 2025. Roche Holding AG maintains a global presence with operations in more than 130 countries, substantial manufacturing and R&D facilities in the United States including Genentech as a wholly owned subsidiary and a majority stake in Chugai Pharmaceutical in Japan. Founded in 1896 and headquartered in Basel, Switzerland, the company pursues recent strategic expansions including a USD 50 billion investment over five years announced in 2025 for new US R&D centres in Massachusetts focused on AI and cardiovascular-metabolic research, expanded manufacturing in Indiana for continuous glucose monitoring and weight loss medicines, gene therapy facilities in Pennsylvania and upgrades across multiple states creating over 12,000 jobs; it entered a definitive merger agreement in September 2025 to acquire 89bio for up to USD 3.5 billion to bolster its CVRM portfolio with pegozafermin for moderate to severe MASH; other moves encompass the 2024 acquisition of Carmot Therapeutics for USD 2.7 billion, 2023 purchase of Televant Holdings for USD 7.1 billion, partnerships like the antibody-drug conjugate deal with Innovent Biologics and licensing of CDK inhibitors from Regor Pharmaceuticals.
Company News
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Roche outlines plans to move towards autonomous AI labs
NTHM's Index Rebalance Puts Thematic Rotation to Work
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Roche: Latest Obesity Data Suggests Pharma Is In Line To Become Global GLP-1 Player
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche proposes former Takeda CEO for board seat
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Roche signs global licensing pact for Simcere's experimental blood cancer drug
U.S.' 'win' in the war has been choking off Iran's oil exports: David Roche
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now